| Literature DB >> 35204132 |
Renata Candido da Silva1, Bertha Furlan Polegato1, Paula Shmidt Azevedo1, Ana Angélica Fernandes2, Katashi Okoshi1, Sergio Alberto Rupp de Paiva1, Marcos Ferreira Minicucci1, Leonardo Antônio Mamede Zornoff1.
Abstract
The cardiac remodeling after myocardial infarction is characterized by inflammation and oxidative stress. Thus, this study aimed to test the hypothesis that jaboticaba, due to its anti-inflammatory and antioxidants properties, attenuates cardiac remodeling after myocardial infarction. Wistar rats were submitted to myocardial infarction due to coronary artery occlusion, and divided into four experimental groups: C, sham control animals; I, animals submitted to myocardial infarction, received a standard diet; IJ2, animals submitted to myocardial infarction, received a standard diet plus 2% jaboticaba; and IJ4, animals submitted to myocardial infarction, received a standard diet plus 4% jaboticaba. After a three-month follow-up, echocardiography, histology, oxidative stress, and cardiac energy metabolism were analyzed. There was no difference in infarct size or mortality among the infarcted groups. The IJ4 group displayed improved diastolic function, as assessed by isovolumetric relaxation time normalized to the heart rate. As expected, the percentage of collagen was higher in all infarcted groups than in the C group. However, the IJ2 group had less collagen than groups I and IJ4. The IJ4 group presented lower PFK activity than I and IJ2, and lower pyruvate dehydrogenase activity than controls, whereas the IJ2 group showed no differences compared to the control group in both LDH and ATP synthase activity. The 2% and 4% doses attenuated lipid peroxidation and increased the activity of glutathione peroxidase compared with the I group. In conclusion, jaboticaba attenuated the remodeling process after myocardial infarction, which was associated with decreased oxidative stress and improved energy metabolism.Entities:
Keywords: cardiac remodeling; energy metabolism; fibrosis; jaboticaba; oxidative stress
Year: 2022 PMID: 35204132 PMCID: PMC8868135 DOI: 10.3390/antiox11020249
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Initial and final body weight and daily feed intake.
| Variables | C ( | I ( | IJ2 ( | IJ4 ( |
|---|---|---|---|---|
| Initial body weight (g) | 251 ± 19 | 239 ± 16 | 247 ± 23 | 245 ± 24 |
| Final body weight (g) | 379 ± 30 | 388 ± 25 | 400 ± 35 | 386 ± 32 |
| Feed intake (g/day) | 20 (19–22) | 21 (19–22) | 20 (19–21) | 19 (18–20) |
C: control animals; I: infarcted animals; IJ2: infarcted animals supplemented with jaboticaba 2%; IJ4: infarcted animals supplemented with jaboticaba 4%. Data are expressed as the mean ± SD or median (including the lower quartile and upper quartile). p > 0.05.
Echocardiographic data.
| Variables | C | I | IJ2 | IJ4 |
|---|---|---|---|---|
| LA (mm) | 5.4 ± 0.6 | 6.2 ± 0.9 * | 6.5 ± 0.8 * | 6.4 ± 0.8 * |
| LVDD (mm) | 7.1 ± 0.7 | 9.2 ± 0.5 * | 9.3 ± 0.7 * | 9.4 ± 0.7 * |
| LVSD (mm) | 2.8 ± 0.6 | 7.0 ± 0.6 * | 7.1 ± 0.8 * | 7.1 ± 0.9 * |
| EF (%) | 0.9 ± 0.1 | 0.5 ± 0.1 * | 0.5 ± 0.1 * | 0.6 ± 0.1 * |
| FAC (%) | 77 ± 6.7 | 35 ± 7.7 * | 33 ± 7.6 * | 32 ± 12 * |
| EDT | 43 ± 7.1 | 47 ± 6.8 * | 51 ± 11 * | 51 ± 10 * |
| IRT/RR0.5 | 52 ± 7.0 | 62 ± 10 * | 64 ± 9.5 * | 59 ± 10 |
C: control animals; I: infarcted animals; IJ2: infarcted animals supplemented with jaboticaba 2%; IJ4: infarcted animals supplemented with jaboticaba 4%. LA, left atrium diameter; LVDD, left ventricular (LV) diastolic diameter; LVSD, LV systolic diameter; EF, ejection fraction; FAC, fractional area change; EDT, E wave deceleration time; IRT/RR, isovolumetric relaxation time normalized by heart rate. Data are expressed as the mean ± SD. All animals were subjected to an echocardiogram. * p < 0.05 versus C.
Figure 1Myocyte Cross-Sectional Area. (A) control animals; (B) infarcted animals; (C) infarcted animals supplemented with jaboticaba 2%; (D) infarcted animals supplemented with jaboticaba 4%.
Figure 2Interstitial Collagen Volume Fraction. (A) control animals; (B) infarcted animals; (C) infarcted animals supplemented with jaboticaba 2%; (D) infarcted animals supplemented with jaboticaba 4%.
Cardiac energy metabolism assessment.
| Variables | C ( | I ( | IJ2 ( | IJ4 ( |
|---|---|---|---|---|
| Phosphofructokinase (nmol/g) | 148 ± 29 | 355 ± 78 *# | 340 ± 99 *# | 134 ± 62 |
| Pyruvate dehydrogenase complex (nmol/g) | 282 ± 30 | 212 ± 56 | 244 ± 35 | 186 ± 37 * |
| Lactate dehydrogenase (nmol/g) | 61 ± 10 | 92 ± 28 * | 78 ± 14 | 91 ± 24 * |
| β-Hydroxyacyl-CoA dehydrogenase (nmol/mg) | 26 ± 5 | 10 ± 3 * | 8 ± 2 * | 9 ± 3 * |
| Citrate synthase (nmol/g) | 31 ± 6 | 16 ± 3 * | 17 ± 3* | 16 ± 3 * |
| Complex I (NADH dehydrogenase) (nmol/mg) | 10 ± 1 | 6 ± 1 * | 5 ± 1 * | 5 ± 1 * |
| Complex II (Succinate dehydrogenase) (nmol/mg) | 4.87 ± 0.88 | 2.75 ± 0.54 * | 2.88 ± 0.98 * | 2.55 ± 0.48 * |
| ATP synthase (nmol/mg) | 30 ± 5 | 18 ± 4 * | 23 ± 4 | 16 ± 4 * |
C: control animals; I: infarcted animals; IJ2: infarcted animals supplemented with jaboticaba 2%; IJ4: infarcted animals supplemented with jaboticaba 4%. Data are expressed as the mean ± SD. * p < 0.05 versus C; # p < 0.05 versus IJ4.
Oxidative stress assessment.
| Variables | C ( | I ( | IJ2 ( | IJ4 ( |
|---|---|---|---|---|
| LH (nmol/mg of tissue) | 244 ± 34 | 325 ± 45 * | 289 ± 42 | 234 ± 39 |
| CP (nmol/mg of protein) | 2.8 ± 0.4 | 4.7 ± 0.6 * | 4.4 ± 0.9 * | 4.9 ± 0.8 * |
| CAT (µmol/g of tissue) | 53 ± 6.8 | 37 ± 5.2 * | 34 ± 6.4 * | 34 ± 7.4 * |
| SOD (nmol/mg of tissue) | 15 ± 3.1 | 11 ± 1.3 * | 9.9 ± 1.8 * | 11 ± 1.9 * |
| GSH-Px (nmol/mg of tissue) | 41 ± 8.9 | 28 ± 6.7 * | 43 ± 9.2 | 41 ± 8.3 |
C: control animals; I: infarcted animals; IJ2: infarcted animals supplemented with jaboticaba 2%; IJ4: infarcted animals supplemented with jaboticaba 4%. LH: lipid hydroperoxide; CP: carbonyl protein; CAT: catalase; SOD: superoxide dismutase; GSH-Px: glutathione peroxidase. Data are expressed as the mean ± SD. * p < 0.05 versus C.
Figure 3Nrf-2 levels. C: control animals; I: infarcted animals; IJ2: infarcted animals supplemented with jaboticaba 2%; IJ4: infarcted animals supplemented with jaboticaba 4%. * p < 0.05 versus C.